Overview
Services

Soiken Holdings Inc.

Soi Research Holdings is an Osaka University-derived bioventure holding company operating across five segments: Biological Evaluation Systems, Healthcare Support, Cosmetics, Health Supplements, and Functional Ingredient Development. Its core subsidiary, Sogo Igaku Kenkyusho, develops proprietary biomarkers and biological evaluation systems for clinical testing of food and pharmaceutical products, while other subsidiaries market placenta-based cosmetics (BB Laboratories), fatigue-targeting health supplements (imidapeptide), and lactoferrin-based functional ingredients (NRL Pharma). The group leverages its biomarker technology and medical institution network to support health insurance societies with disease prevention programs and specific health checkup services.

Market Cap
¥5.68B
US$36.2M
EV
¥-0.00B
-US$0.01M
Stock¥217▲+0.00%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
26.8
x
LTM PBR
0.9
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-7.7%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
5.68BUS$36.2MMarket Cap0.00BUS$0.00M+ Debt5.35BUS$34.1M− Cash0.33BUS$2.07M− Inv. Sec.-0.00B-US$0.01MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
9.35US$59.6M'22/68.08US$51.5M'23/65.16US$32.9M'24/64.85US$30.9M'25/63.87US$24.7M'26/6
EBITDA 5Y (¥B)
1.23US$7.83M'22/60.75US$4.78M'23/6-0.58-US$3.72M'24/6-0.12-US$0.76M'25/60.29US$1.84M'26/6
Net Income 5Y (¥B)
0.81US$5.16M'22/60.45US$2.88M'23/6-0.66-US$4.22M'24/6-0.21-US$1.34M'25/60.21US$1.35M'26/6
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
6.04US$38.5M'22/65.97US$38.1M'23/64.80US$30.6M'24/64.98US$31.8M'25/65.38US$34.3M'26/6
Shareholders
Top 10 hold 45.7%
1
GOLONG HOLDING CO.,LIMITED (Standing Proxy: Mita Securities Co., Ltd.)
17.68%
2
Osami KAJIMOTO
16.92%
3
Hikari Tsushin KK Investment Business Limited Liability Partnership
3.45%
4
Yosuke HOSOKAWA
1.76%
5
Kenjiro AMANO
1.35%
6
Takahiro YAMASHITA
1.22%
7
INTERACTIVE BROKERS LLC (Standing Proxy: Interactive Brokers Securities Japan Inc.)
0.90%
8
Toshio ICHIKAWA
0.86%
9
UH6 Co., Ltd.
0.78%
10
Akihiro HAYASHISHITA
0.74%
Management
9 officers
Kentaro ISHIGAMI
Director, Chairman of the Board
Apr 1996 Joined LCA Japan Co., Ltd. Jun 2005 Joined the Company, General Affairs Department Nov 2007 Director, Nippon Yobou Iyakuhin Co., Ltd. Sep 2009 Representative Director, President, Nippon Yobou Iyakuhin Co., Ltd. Sep 2015 Director of the Company Jan 2018 Representative Director, President of the Company Sep 2018 Representative Director, President, Evidence Lab Co., Ltd. Sep 2021 Director, NRL Pharma Co., Ltd. Jul 2024 Representative Director, President, BB Laboratories Co., Ltd. Aug 2026 Director, Chairman of the Board of the Company (current) Representative Liquidator, BB Laboratories Co., Ltd. (current)
1973-01-05
Masao KAKUDA
Representative Director, President
Apr 2003 Joined Roche Diagnostics K.K. Jul 2007 Joined Sogo Iryo Kagaku Kenkyujo Co., Ltd., Planning Office Oct 2008 General Manager, Healthcare Support Business Division, Sogo Iryo Kagaku Kenkyujo Co., Ltd. Sep 2010 Director, Sogo Iryo Kagaku Kenkyujo Co., Ltd. Jun 2017 Representative Director, Senior Managing Director, NRL Pharma Co., Ltd. Sep 2019 Director of the Company Jul 2020 Representative Director, President, NRL Pharma Co., Ltd. Sep 2024 Representative Director, President of the Company (current) Sep 2024 Representative Director, President, Sogo Iryo Kagaku Kenkyujo Co., Ltd. (current) Sep 2024 Representative Director, President, Nippon Yobou Iyakuhin Co., Ltd. (current)
1977-07-14
Osami KAJIMOTO
Director (Part-time)
Mar 1994 Completed Doctoral Program, Graduate School of Medicine, Osaka University (Ph.D. in Medicine) Jul 1994 Representative Director of the Company Jun 1997 Resigned as Representative Director of the Company Jul 1997 Lecturer, Health Care Center, Osaka University of Foreign Studies (now Osaka University) Dec 1999 Associate Professor, Health Care Center, Osaka University of Foreign Studies (now Osaka University) Dec 2002 Director of the Company (current) May 2007 Professor, COE Biomedical Information Analysis, Graduate School of Medicine, Osaka City University (now Osaka Metropolitan University) May 2010 Specially Appointed Professor, Fatigue Medicine, Graduate School of Medicine, Osaka City University (now Osaka Metropolitan University) Nov 2010 Representative Director, Econavista Co., Ltd. Aug 2015 Opened Tokyo Fatigue and Sleep Clinic; Director, Clinic Head (current) May 2017 Chairman of the Board, Econavista Co., Ltd. Jul 2025 Senior Advisor, Econavista Co., Ltd. (current)
1962-03-24
Takahito OKUNO
Director, General Manager of Finance Department
Apr 2000 Joined Eco Trading Co., Ltd. Sep 2017 Joined Yumetenbou Co., Ltd. Jun 2020 Joined the Company, Finance Department Jul 2022 Deputy General Manager, Finance Department of the Company Nov 2022 Joined Eena Co., Ltd. Jan 2023 General Manager, Management Administration Department, Eena Co., Ltd. Mar 2023 General Manager, Management Division, Eena Co., Ltd. Sep 2023 Joined the Company, General Manager, Finance Department (current) Sep 2023 Director, NRL Pharma Co., Ltd. Sep 2024 Director of the Company (current) Sep 2024 Director, Sogo Iryo Kagaku Kenkyujo Co., Ltd. (current) Sep 2025 Director, Nippon Yobou Iyakuhin Co., Ltd. (current)
1977-06-08
Masakazu NAKAJIMA
Director
Apr 1996 Joined Itochu Corporation Apr 2000 Joined CyberAgent, Inc. Aug 2001 Joined Schroder Ventures K.K. (now MKS Partners) Oct 2006 Joined Macquarie Capital Oct 2010 Founded Brightlink Partners Co., Ltd.; Representative Director (current) Sep 2011 Founded Welby Co., Ltd.; Director Apr 2016 Founded NexGen Co., Ltd.; Representative Director Aug 2016 Director (Audit and Supervisory Committee Member), Welby Co., Ltd. Sep 2020 Outside Director of the Company (current) Mar 2021 Founded Curvegen Co., Ltd.; Representative Director (current) Nov 2024 Representative Director, NexGen Co., Ltd. (current)
1974-01-02
Hiroyuki YAMAMOTO
Director
Apr 1976 Joined Nomura Securities Co., Ltd. Jul 1993 President, Nomura Middle East Investment Bank Jul 1997 Branch Manager, Seoul Branch, Nomura Securities Co., Ltd. Jul 2001 General Manager, Investment Research Department, Head Office, Nomura Securities Co., Ltd. Jul 2003 President, Banque Nomura France Jul 2009 General Manager, Financial Institutions Marketing Department, Nomura Asset Management Co., Ltd. Apr 2011 Part-time Lecturer, Graduate School of Osaka University of Economics Apr 2014 Professor, Teikyo University Junior College Apr 2016 Professor, Faculty of Economics, Teikyo University Jun 2018 Director, Maison franco-japonaise (Public Interest Foundation) (current) Sep 2023 Outside Director of the Company (current)
1953-01-11
Kazuhiro HAYASHI
Full-time Audit & Supervisory Board Member
Apr 1978 Joined Toucho Advertising Co., Ltd. Oct 1980 Joined Satsuki Juku Apr 2001 Joined the Company Dec 2001 Representative Director, President of the Company Jul 2003 Advisor of the Company Sep 2008 Full-time Audit & Supervisory Board Member of the Company (current)
1952-12-29
Naoshi ICHIDA
Audit & Supervisory Board Member
Dec 2013 Joined Osaka Senba Law Office (now Osaka Senba Law Office, Attorney Corporation) Aug 2020 Provisional Audit & Supervisory Board Member of the Company Sep 2020 Outside Audit & Supervisory Board Member of the Company (current) Jan 2024 Opened Ichida Sogo Law Office; Office Head (current)
1985-12-26
Reri FURUYA
Audit & Supervisory Board Member
Apr 1992 Joined Nomura Securities Co., Ltd. Oct 1996 Joined Ota Showa Audit Corporation (now EY ShinNihon LLC) Apr 1999 Registered as Certified Public Accountant Apr 2004 Joined Nomura Securities Co., Ltd. May 2020 Opened Furuya Certified Public Accountant Office; Office Head (current) Sep 2020 Outside Audit & Supervisory Board Member of the Company (current) Apr 2022 Outside Audit & Supervisory Board Member, Quortech Co., Ltd. (current) Jun 2026 Outside Director (Audit and Supervisory Committee Member), Nakamoto Packs Co., Ltd. (current) Outside Director (Audit and Supervisory Committee Member), Fuji Shoji Co., Ltd. (current)
1969-08-08
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-09-24
Annual Securities Report
Period: Jul 2025 – Jun 2026
TDnet
2026-08-12
Full-Year Earnings Flash
FY ending Jun 2026
TDnet
2026-05-13
Q3 Earnings Flash
FY ending Jun 2026
EDINET
2026-02-13
Semi-Annual Securities Report
Period: Jul 2025 – Jun 2026
TDnet
2025-11-13
Q1 Earnings Flash
FY ending Jun 2026
EDINET
2025-09-24
Annual Securities Report
Period: Jul 2024 – Jun 2025
TDnet
2025-05-13
Q3 Earnings Flash
FY ending Jun 2025
EDINET
2025-02-13
Semi-Annual Securities Report
Period: Jul 2024 – Jun 2025
TDnet
2024-11-13
Q1 Earnings Flash
FY ending Jun 2025
EDINET
2024-09-27
Annual Securities Report
Period: Jul 2023 – Jun 2024
EDINET
2024-05-14
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-13
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-09-28
Annual Securities Report
Period: Jul 2022 – Jun 2023
EDINET
2023-05-12
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-02-13
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-14
Quarterly Securities Report
EDINET
2022-09-29
Annual Securities Report
EDINET
2022-05-13
Quarterly Securities Report
EDINET
2022-02-14
Quarterly Securities Report
EDINET
2021-11-12
Quarterly Securities Report
EDINET
2021-09-29
Annual Securities Report
EDINET
2021-05-13
Quarterly Securities Report
EDINET
2021-02-12
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →